Paul Duell, MD
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1265448864
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,329 of the $90,650 with a category attached, or 72.1%. 21 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.0% of the total. Among endocrinology, diabetes & metabolism clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $749.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$24K
- Ionis Pharmaceuticals, Inc.$14K
- Regeneron$13K
- Mirum Pharmaceuticals, Inc.$12K
- Kaneka Medical America LLC$5K
- Sanofi-aventis U.S. LLC$4K
- plus $18K from 15 others
Across 172 payments — averaging $2177.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$246K
- Regeneron$129K
What the payments were for
- Consulting fees$65,32972%
- Speaking & faculty fees$9,90211%
- Travel & lodging$10,47712%
- Food & beverage$4,9425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 26 | $23,606 |
| Ionis Pharmaceuticals, Inc. | 14 | $14,399 |
| Regeneron | 14 | $13,288 |
| Mirum Pharmaceuticals, Inc. | 10 | $12,028 |
| Kaneka Medical America LLC | 9 | $5,279 |
| Sanofi-aventis U.S. LLC | 4 | $4,191 |
| Akcea Therapeutics, Inc. | 2 | $4,000 |
| Sanofi Pasteur Inc. | 1 | $2,244 |
| Amryt Pharma Holdings Ltd | 1 | $2,150 |
| Novo Nordisk | 7 | $2,078 |
| Amarin Pharma, Inc. | 3 | $2,020 |
| Chiesi USA, Inc. | 1 | $2,000 |
| Amgen | 17 | $1,379 |
| AstraZeneca | 1 | $930 |
| Esperion Therapeutics, Inc. | 4 | $473 |
| Novartis | 2 | $242 |
| Merck | 1 | $91 |
| Kowa Pharmaceuticals America, Inc. | 1 | $88 |
| Madrigal Pharmaceuticals | 1 | $83 |
| Travere Therapeutics, Inc. | 1 | $52 |
| Vifor Pharma, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,650 in reported general payments places this provider in the 90th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ChenodalChenodiol | 25 | $1,183,658 |
| Repatha SureclickEvolocumab | 156 | $193,276 |
| OzempicSemaglutide | 115 | $161,050 |
| JardianceEmpagliflozin | 73 | $100,766 |
| NexletolBempedoic Acid | 100 | $89,455 |
| Praluent PenAlirocumab | 79 | $78,627 |
| MounjaroTirzepatide | 65 | $66,180 |
| TrulicityDulaglutide | 54 | $62,436 |
| GenotropinSomatropin | 22 | $47,554 |
| VascepaIcosapent Ethyl | 35 | $29,990 |
| FarxigaDapagliflozin Propanediol | 25 | $27,667 |
| LivaloPitavastatin Calcium | 34 | $21,770 |
| EliquisApixaban | 11 | $20,810 |
| Ezetimibe | 652 | $16,633 |
| Icosapent Ethyl | 40 | $16,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,078 | $161,050115 claims |
| Esperion Therapeutics, Inc.Nexletol | $473 | $89,455100 claims |
| AstraZenecaFarxiga | $930 | $27,66725 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $88 | $21,77034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Portland
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Eric OrwollPortland$94K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Andrew AhmannPortland$56K
- Matthew RiddlePortland$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.